Latest Breaking News On - Approvals boost opdivo and gardasil - Page 1 : comparemela.com

Share this article Share this article ResearchAndMarkets.com s offering. Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently three approved vaccines for HPV: Cervarix, Gardasil, and Gardasil 9. Merck & Co s Gardasil, a quadrivalent vaccine, was first-to-market with its debut in 2006, narrowly ahead of the 2007 release of GlaxoSmithKline s rival bivalent vaccine, Cervarix. Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs). In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil. Since the launch of the first HPV vaccine in 2006, the market has seen steady growth, with global sales rising from $235m in 2006 to $2.3bn in 2016. This growth was attributed to the launch of vaccination programs in most major markets, ce

United kingdomLaura woodE st office hours callMerck co gardasilOffice hours callMerck coHuman papillomavirusTopics coveredApprovals boost opdivo and gardasilSenior managerFree callHours callResearch and marketsஒன்றுபட்டது கிஂக்டம்லாரா மரம்ஏ ஸ்டம்ப் அலுவலகம் மணி அழைப்பு